Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 157
Filtrar
1.
BMC Infect Dis ; 20(1): 393, 2020 Jun 03.
Artigo em Inglês | MEDLINE | ID: mdl-32493234

RESUMO

BACKGROUND: Dengue is a mosquito-borne viral infection which has been estimated to cause a global economic burden of US$8.9 billion per year. 40% of this estimate was due to what are known as productivity costs (the costs associated with productivity loss from both paid and unpaid work that results from illness, treatment or premature death). Although productivity costs account for a significant proportion of the estimated economic burden of dengue, the methods used to calculate them are often very variable within health economic studies. The aim of this review was to systematically examine the current estimates of the productivity costs associated with dengue episodes in Asia and to increase awareness surrounding how productivity costs are estimated. METHOD: We searched PubMed and Web of Knowledge without date and language restrictions using terms related to dengue and cost and economics burden. The titles and abstracts of publications related to Asia were screened to identify relevant studies. The reported productivity losses and costs of non-fatal and fatal dengue episodes were then described and compared. Costs were adjusted for inflation to 2017 prices. RESULTS: We reviewed 33 relevant articles, of which 20 studies reported the productivity losses, and 31 studies reported productivity costs. The productivity costs varied between US$6.7-1445.9 and US$3.8-1332 for hospitalized and outpatient non-fatal episodes, respectively. The productivity cost associated with fatal dengue episodes varied between US$12,035-1,453,237. A large degree of this variation was due to the range of different countries being investigated and their corresponding economic status. However, estimates for a given country still showed notable variation. CONCLUSION: We found that the estimated productivity costs associated with dengue episodes in Asia are notable. However, owing to the significant variation in methodology and approaches applied, the reported productivity costs of dengue episodes were often not directly comparable across studies. More consistent and transparent methodology regarding the estimation of productivity costs would help the estimates of the economic burden of dengue be more accurate and comparable across studies.


Assuntos
Efeitos Psicossociais da Doença , Dengue/economia , Custos de Cuidados de Saúde , Ásia , Cuidadores/economia , Bases de Dados Factuais , Dengue/patologia , Hospitalização/estatística & dados numéricos , Humanos
2.
Am J Trop Med Hyg ; 102(6): 1237-1243, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32314702

RESUMO

Dengue fever is a predominantly imported infectious disease in Japan. However, domestic dengue infections were found in 2014. The economic burden of dengue is informative to formulate a policy toward its control. We estimated patient and societal economic burden of dengue infections in Japan from the restricted societal perspective. The direct medical cost was estimated from the national claims database between 2011 and 2015, and the indirect cost was estimated by multiplying the treatment days with the average wage. The average number of dengue patients per year was 274. The economic burden per dengue patient was $1,364.90 (direct medical cost: $1,213.80 and indirect cost: $151.10); the average economic burden for dengue in Japan per year was $433,217 (direct cost: $329,557, indirect cost: $41,298, and nonmedical cost: $62,362). We estimated the economic burden of dengue per patient and year in Japan from 2011 to 2015. The economic burden per year was not huge. It may not be necessary to formulate the National Prevention Plan for dengue. However, domestic dengue outbreak might occur again in the future. Preventive action should be taken with considering cost-effectiveness or budget impact. The findings in this study may be of use for these health economic analyses for planning prevention strategy for not only dengue but also other mosquito-borne diseases.


Assuntos
Efeitos Psicossociais da Doença , Dengue/economia , Dengue/epidemiologia , Surtos de Doenças , Custos de Cuidados de Saúde , Adulto , Idoso , Feminino , Humanos , Japão/epidemiologia , Masculino , Pessoa de Meia-Idade , Adulto Jovem
3.
Int J Infect Dis ; 94: 59-67, 2020 May.
Artigo em Inglês | MEDLINE | ID: mdl-32179138

RESUMO

BACKGROUND: We assessed the cost-effectiveness of Camino Verde, a community-based mobilization strategy to prevent and control dengue and other mosquito-borne diseases. A cluster-randomized controlled trial in Managua, Nicaragua, and in three coastal regions in Guerrero, Mexico (75 intervention and 75 control clusters), Camino Verde used non-governmental community health workers, called brigadistas, to support community mobilization. This donor-funded trial demonstrated reductions of 29.5% (95% confidence interval, CI: 3.8%-55.3%) on dengue infections and 24.7% (CI: 1.8%-51.2%) on self-reported cases. METHODS: We estimated program costs through a micro-costing approach and semi-structured questionnaires. We show results as incremental cost-effectiveness ratios (ICERs) for costs per disability-adjusted life-year (DALYs) averted and conducted probabilistic sensitivity analyses. FINDINGS: The Camino Verde trial spent US$16.72 in Mexico and $7.47 in Nicaragua per person annually. We found an average of 910 (CI: 487-1 353) and 500 (CI: 250-760) dengue cases averted annually per million population in Mexico and Nicaragua, respectively, compared to control communities. The ICER in Mexico was US$29 618 (CI: 13 869-66 898) per DALY averted, or 3.0 times per capita GDP. For Nicaragua, the ICER was US$29 196 (CI: 14294-72181) per DALY averted, or 16.9 times per capita GDP. INTERPRETATION: Camino Verde, as implemented in the research context, was marginally cost-effective in Mexico, and not cost-effective in Nicaragua, from a healthcare sector perspective. Nicaragua's low per capita GDP and the use of grant-funded management personnel weakened the cost-effectiveness results. Achieving efficiencies by incorporating Camino Verde activities into existing public health programs would make Camino Verde cost-effective.


Assuntos
Medicina Comunitária/métodos , Dengue/prevenção & controle , Mosquitos Vetores , Aedes , Animais , Análise por Conglomerados , Análise Custo-Benefício , Dengue/economia , Dengue/epidemiologia , Vírus da Dengue , Humanos , México , Controle de Mosquitos , Nicarágua
4.
Artigo em Inglês | MEDLINE | ID: mdl-32164392

RESUMO

Located in the subtropics, Taiwan is one of the major epidemic areas for dengue fever, with severe epidemics occurring in recent years. Dengue fever has become a serious health threat to Taiwan's residents and a potentially serious economic cost to society. This study recruited 730 random participants and adopted the contingent valuation method to understand the factors influencing the populace's willingness to pay (WTP) to reduce the health risk of dengue fever. The results show that high-income women with children and people with higher preventive perceptions and behavior are more willing to invest in preventive measures against dengue fever. In the evaluation of WTP for preventive treatment for health risks, each person was willing to pay on average NT$751 annually to lower psychological health risks, NT$793 annually to lower the risk of illness, and NT$1086 annually to lower the risk of death.


Assuntos
Dengue , Serviços de Saúde , Criança , Dengue/economia , Dengue/prevenção & controle , Feminino , Serviços de Saúde/economia , Humanos , Renda , Masculino , Risco Ajustado/economia , Risco Ajustado/estatística & dados numéricos , Taiwan , Valor da Vida
5.
PLoS One ; 15(1): e0227409, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-31914143

RESUMO

BACKGROUND: Febrile illness caused by viral and bacterial diseases (e.g., dengue and leptospirosis) often have similar symptoms and are difficult to differentiate without diagnostic tests. If not treated appropriately, patients may experience serious complications. The question of what diagnostic tests to make available to providers in order to inform antibiotic therapy remains an open problem for health services facing limited resources. METHODS AND FINDINGS: We formulated the problem of minimizing the weighted average of antibiotic underuse and overuse to inform the optimal diagnostic test and antibiotic treatment options for given occurrence probabilities of several bacterial and viral infections. We modeled the weight of antibiotic overuse as a monetary penalty per unnecessarily administered course, which we varied in both the base case and sensitivity analysis. Detailed Markov cohort models of febrile illness progression were used to estimate the weight of antibiotic underuse. The model accounted for multiple infections simultaneously and incorporated test, treatment, and other direct and indirect costs, as well as the effect of delays in seeking care and test turnaround times. We used the Markov models to numerically estimate disability-adjusted life years (DALYs), pre-penalty costs, and likelihood of antibiotics overuse per patient for fifteen different strategies in two example settings in Thailand, one with a higher probability of bacterial infections (Northern Thailand, Scenario A) and one with a higher probability of viral infections (Bangkok, Scenario B). We found that empirical antibiotic treatment to all patients always incurs the lowest pre-penalty cost (Scenario A: $47.5/patient, $100.6/patient, $149.5/patient for patients seeking care on day one, day four, and day ten respectively; Scenario B: $94.1/patient, $108.7/patient, $122.1/patient on day one, day four, and day ten respectively), and the lowest DALYs, (Scenario A: 0.2 DALYs/patient, 0.9 DALYs/patient, 1.7 DALYs/patient on day one, day four, and day ten, respectively; Scenario B: 0.5 DALYs/patient, 0.7 DALYs/patient, 0.9 DALYs/patient on day one, day four, and day ten, respectively). However, such strategy resulted in the highest proportion of antibiotic overuse per patient (Scenario A: 38.1%, 19.3%, 7.5% on day one, day four, and day ten, respectively; Scenario B: 82.9%, 42.1%, 16.3% on day one, day four, and day ten, respectively). Consequently, empirical antibiotic treatment became suboptimal with antibiotic overuse penalties above $12,800/course, $18,400/course, $23,900/course for patients presenting on day one, day four, and day ten in Scenario A and above $1,100/course, $1,500/course, $1,600/course for patients presenting on day one, day four, and day ten in Scenario B. CONCLUSIONS: Empirical antibiotic treatment to all patients provided the best outcomes if antibiotic overuse was not the primary concern or if presenting with viral disease (such as dengue) was unlikely. Empirical antibiotic treatment to severe patients only was in most cases not beneficial. Otherwise, strategies involving diagnostic tests became optimal. In particular, our results indicated that single test strategies (bacterial RDT or viral PCR) were optimal in regions with a greater probability of presenting with viral infection. PCR-led strategies (e.g., parallel bacterial PCR, or multiplex PCR) are robust under parameter uncertainty (e.g., with uncertain disease occurrence probabilities).


Assuntos
Antibacterianos , Dengue , Leptospirose , Modelos Biológicos , Modelos Econômicos , Antibacterianos/economia , Antibacterianos/uso terapêutico , Custos e Análise de Custo , Dengue/diagnóstico , Dengue/tratamento farmacológico , Dengue/economia , Dengue/epidemiologia , Feminino , Humanos , Leptospirose/diagnóstico , Leptospirose/tratamento farmacológico , Leptospirose/economia , Leptospirose/epidemiologia , Masculino , Tailândia/epidemiologia
6.
Artigo em Inglês | MEDLINE | ID: mdl-31991624

RESUMO

Dengue has long been a public health problem in tropical and subtropical countries. In 2015, a dengue outbreak occurred in Taiwan, where 43,784 cases were reported. This study aims to assess the impact of dengue on Southern Taiwan's economic growth according to the economic growth model-based regression approach recommended by the World Health Organization (WHO). Herein, annual data from Southern Taiwan on the number of dengue cases, income growth, and demographics from 2010-2015 were analyzed. The percentage of reduction of the average income per capita in 2015 due to the dengue outbreak was estimated. Dengue was determined to have a negative linear economic impact on Southern Taiwan's economic growth. In particular, a reduction of 0.26% in the average income per capita was estimated in Southern Taiwan due to the 2015 outbreak. If the model is applied alongside other dengue outbreak forecast models, then the forecast for economic reduction due to a future dengue outbreak may also be estimated. Prevention and recovery policies may subsequently be decided upon based on not only the number of dengue cases but also the degree of economic burden resulting from an outbreak.


Assuntos
Efeitos Psicossociais da Doença , Dengue/economia , Dengue/epidemiologia , Surtos de Doenças/economia , Desenvolvimento Econômico , Dengue/mortalidade , Surtos de Doenças/estatística & dados numéricos , Feminino , Custos de Cuidados de Saúde , Humanos , Renda , Masculino , Perfil de Impacto da Doença , Taiwan
7.
Parasit Vectors ; 13(1): 32, 2020 Jan 17.
Artigo em Inglês | MEDLINE | ID: mdl-31952539

RESUMO

BACKGROUND: Dengue is a mosquito-borne viral disease caused by one of four serotypes (DENV1-4). Infection provides long-term homologous immunity against reinfection with the same serotype. Plaque reduction neutralization test (PRNT) is the gold standard to assess serotype-specific antibody levels. We analysed serotype-specific antibody levels obtained by PRNT in two serological surveys conducted in Singapore in 2009 and 2013 using cluster analysis, a machine learning technique that was used to identify the most common histories of DENV exposure. METHODS: We explored the use of five distinct clustering methods (i.e. agglomerative hierarchical, divisive hierarchical, K-means, K-medoids and model-based clustering) with varying number (from 4 to 10) of clusters for each method. Weighted rank aggregation, an evaluating technique for a set of internal validity metrics, was adopted to determine the optimal algorithm, comprising the optimal clustering method and the optimal number of clusters. RESULTS: The K-means algorithm with six clusters was selected as the algorithm with the highest weighted rank aggregation. The six clusters were characterised by (i) dominant DENV2 PRNT titres; (ii) co-dominant DENV1 and DENV2 titres with average DENV2 titre > average DENV1 titre; (iii) co-dominant DENV1 and DENV2 titres with average DENV1 titre > average DENV2 titre; (iv) low PRNT titres against DENV1-4; (v) intermediate PRNT titres against DENV1-4; and (vi) dominant DENV1-3 titres. Analyses of the relative size and age-stratification of the clusters by year of sample collection and the application of cluster analysis to the 2009 and 2013 datasets considered separately revealed the epidemic circulation of DENV2 and DENV3 between 2009 and 2013. CONCLUSION: Cluster analysis is an unsupervised machine learning technique that can be applied to analyse PRNT antibody titres (without pre-established cut-off thresholds to indicate protection) to explore common patterns of DENV infection and infer the likely history of dengue exposure in a population.


Assuntos
Vírus da Dengue/imunologia , Dengue/epidemiologia , Adolescente , Adulto , Distribuição por Idade , Algoritmos , Anticorpos Antivirais/sangue , Análise por Conglomerados , Estudos Transversais , Dengue/economia , Dengue/imunologia , Vírus da Dengue/classificação , Humanos , Pessoa de Meia-Idade , Testes de Neutralização , Reprodutibilidade dos Testes , Estudos Soroepidemiológicos , Sorogrupo , Singapura/epidemiologia , Adulto Jovem
8.
Rev. cuba. med. trop ; 71(3): e419, sept.-dic. 2019. tab
Artigo em Espanhol | LILACS, CUMED | ID: biblio-1093582

RESUMO

Introducción: En Cuba no se han estudiado suficientemente los gastos de bolsillo y la pérdida de calidad de vida relacionada con la salud (de pacientes con dengue y sus familiares. Objetivo: Describir la afectación de la calidad de vida, los costos no médicos directos (gastos de bolsillo) e indirectos de pacientes hospitalizados con dengue y sus familiares. Método: Estudio de descripción de costos desde la perspectiva de pacientes y familiares, para los hospitalizados con dengue en el Clínico Quirúrgico Salvador Allende, en noviembre de 2013. En enero-febrero de 2014 se aplicó un cuestionario cerrado de 173 preguntas. Se calcularon la pérdida promedio de calidad de vida relacionada con la salud, los costos no médicos directos y los costos indirectos. Resultados: Durante el episodio de dengue el grupo de edad más afectado fue el de 30-44 años. Predominaron las mujeres (63,3 por ciento). La calidad de vida relacionada con la salud se afectó sensiblemente pasando como promedio de 86,9 el día antes de la enfermedad a 27,8 el día que las personas se sintieron más enfermas. En el momento de la entrevista, el 51 por ciento de los pacientes percibían que no se habían recuperado de la enfermedad. Los pacientes estuvieron hospitalizados como promedio 5 días. Los gastos de bolsillo de pacientes y familiares ascendieron a 61,24 CUC (IC95 por ciento 43,23-79,25 CUC), en que el 66,2 por ciento fue en alimentación y el 13,6 por ciento en transporte. Las pérdidas promedio de ingreso fueron de 25,30 CUC para los pacientes y 4,50 CUC para los familiares. Los costos totales promedio por paciente fueron de 89,25 CUC (IC95 por ciento 67,33-110,29 CUC). Conclusiones: Se evidenció la pérdida de calidad de vida como consecuencia del dengue. Los gastos de bolsillo fueron altos y representan tres veces el valor del salario medio de la Provincia La Habana(AU)


Introduction: Health-related loss of quality of life among dengue patients and their relatives, and unforeseen family expenses incurred for this reason, have not been sufficiently studied in Cuba. Objective: Describe the impact on quality of life, as well as the non-medical direct and indirect unforeseen expenses incurred by patients hospitalized with dengue and their relatives. Method: A cost analysis study was conducted based on data provided by patients hospitalized with dengue in Salvador Allende Clinical Surgical Hospital and their relatives in November 2013. A closed-ended questionnaire of 173 questions was applied in January-February 2014. Estimation was made of average health-related loss of quality of life, direct non-medical costs and indirect costs. Results: The 30-44 years age group was the most harshly affected during the episode. There was a predominance of the female sex (63.3 percent). Health-related quality of life decreased dramatically from an average 86.9 the day before the disease to 27.8 on the day when patients felt the worst. At the time of the interview, 51 percent of the patients perceived that they had not recovered from the disease. Mean hospital stay was 5 days. Unforeseen patient and family expenses rose to 61.24 CUC (CI 95 percent; 43.23-79.25 CUC), of which 66.2 percent was spent on food and 13.6 percent on transport. Average income loss was 25.30 CUC for patients and 4.50 CUC for relatives. Total average cost per patient was 89.25 CUC (CI 95 percent 67.33-110.29 CUC). Conclusions: Evidence was found of loss of quality of life as a result of dengue. Unforeseen expenses were high, representing three times the mean salary in the province of Havana(AU)


Assuntos
Humanos , Masculino , Feminino , Indicadores Econômicos , Gastos em Saúde/ética , Dengue/economia , Qualidade de Vida
9.
Med Decis Making ; 39(8): 1045-1058, 2019 11.
Artigo em Inglês | MEDLINE | ID: mdl-31642362

RESUMO

Purpose. Health interventions can generate positive externalities not captured in traditional, single-disease cost-effectiveness analyses (CEAs), potentially biasing results. We illustrate this with the example of mosquito-borne diseases. When a particular mosquito species can transmit multiple diseases, a single-disease CEA comparing disease-specific interventions (e.g., vaccination) with interventions targeting the mosquito population (e.g., insecticide) would underestimate the insecticide's full benefits (i.e., preventing other diseases). Methods. We developed three dynamic transmission models: chikungunya, dengue, and combined chikungunya and dengue, each calibrated to disease-specific incidence and deaths in Colombia (June 2014 to December 2017). We compared the models' predictions of the incremental benefits and cost-effectiveness of an insecticide (10% efficacy), hypothetical chikungunya and dengue vaccines (40% coverage, 95% efficacy), and combinations of these interventions. Results. Model calibration yielded realistic parameters that produced close matches to disease-specific incidence and deaths. The chikungunya model predicted that vaccine would decrease the incidence of chikungunya and avert more total deaths than insecticide. The dengue model predicted that insecticide and the dengue vaccine would reduce dengue incidence and deaths, with no effect for the chikungunya vaccine. In the combined model, insecticide was more effective than either vaccine in reducing the incidence of and deaths from both diseases. In all models, the combined strategy was at least as effective as the most effective single strategy. In an illustrative CEA, the most frequently preferred strategy was vaccine in the chikungunya model, the status quo in the dengue model, and insecticide in the combined model. Limitations. There is uncertainty in the target calibration data. Conclusions. Failure to capture positive externalities can bias CEA results, especially when evaluating interventions that affect multiple diseases. Multidisease modeling is a reasonable alternative for addressing such biases.


Assuntos
Febre de Chikungunya , Controle de Doenças Transmissíveis/economia , Controle de Doenças Transmissíveis/métodos , Dengue , Inseticidas/economia , Vacinas Virais/economia , Febre de Chikungunya/economia , Febre de Chikungunya/epidemiologia , Febre de Chikungunya/prevenção & controle , Análise Custo-Benefício , Dengue/economia , Dengue/epidemiologia , Dengue/prevenção & controle , Humanos , Inseticidas/uso terapêutico , Vacinas Virais/uso terapêutico
10.
PLoS Negl Trop Dis ; 13(7): e0007482, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-31260441

RESUMO

The tetravalent dengue vaccine CYD-TDV (Dengvaxia) is the first licensed vaccine against dengue, but recent findings indicate an elevated risk of severe disease among vaccinees without prior dengue virus (DENV) exposure. The World Health Organization currently recommends CYD-TDV only for individuals with serological confirmation of past DENV exposure. Our objective was to evaluate the potential health impact and cost-effectiveness of vaccination following serological screening. To do so, we used an agent-based model to simulate DENV transmission with and without vaccination over a 10-year timeframe. Across a range of values for the proportion of vaccinees with prior DENV exposure, we projected the proportion of symptomatic and hospitalized cases averted as a function of the sensitivity and specificity of serological screening. Scenarios about the cost-effectiveness of screening and vaccination were chosen to be representative of Brazil and the Philippines. We found that public health impact depended primarily on sensitivity in high-transmission settings and on specificity in low-transmission settings. Cost-effectiveness could be achievable from the perspective of a public payer provided that sensitivity and the value of a disability-adjusted life-year were both high, but only in high-transmission settings. Requirements for reducing relative risk and achieving cost-effectiveness from an individual perspective were more restricted, due to the fact that those who test negative pay for screening but receive no benefit. Our results predict that cost-effectiveness could be achieved only in high-transmission areas of dengue-endemic countries with a relatively high per capita GDP, such as Panamá (13,680 USD), Brazil (8,649 USD), México (8,201 USD), or Thailand (5,807 USD). In conclusion, vaccination with CYD-TDV following serological screening could have a positive impact in some high-transmission settings, provided that screening is highly specific (to minimize individual harm), at least moderately sensitive (to maximize population benefit), and sufficiently inexpensive (depending on the setting).


Assuntos
Análise Custo-Benefício , Vacinas contra Dengue/economia , Dengue/prevenção & controle , Programas de Rastreamento/economia , Saúde Pública/economia , Vacinação/economia , Anticorpos Neutralizantes , Anticorpos Antivirais/sangue , Simulação por Computador , Dengue/economia , Humanos , Testes Sorológicos/economia , Fatores de Tempo , Vacinação/efeitos adversos , Cobertura Vacinal/estatística & dados numéricos , Organização Mundial da Saúde
11.
Trans R Soc Trop Med Hyg ; 113(11): 661-669, 2019 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-31294808

RESUMO

BACKGROUND: Dengue is major public health problem in India, especially in urban areas. We conducted a study to estimate the severity and costs of treatment among hospitalized dengue patients in Surat city, Gujarat, India. METHODS: We reviewed the medical records of dengue patients hospitalized in five tertiary care facilities (private [n=2], semi-government [n=2] and government [n=1]) between April 2017 and March 2018. We used the World Health Organization 2009 classification to classify the severity of dengue. A resource utilization approach was used to estimate the cost of illness in US dollars (US$) (inflation adjusted to 2018) from a quasi-societal perspective (excluding non-medical cost) for dengue hospitalization. RESULTS: Of the 732 hospitalized dengue patients, 44.7% had no warning symptoms, 39.5% had warning signs and 15.8% had severe dengue. The mean cost of hospitalization was US$86.9±170.7. The cost of hospitalization was 28.8 times higher in private hospitals compared with government hospitals. Consultant charges in private hospitals, laboratory investigations in semi-government hospitals and registration with admission charges in government hospitals accounted for 27.3%, 39.4% and 53% of the direct cost in these facilities, respectively. CONCLUSIONS: A better triage system for hospitalization, subsidizing costs in the public sector and cost capping in the private sector can help to reduce the cost of hospitalization due to dengue so as to ensure affordability for larger portion of the society for universal health coverage.


Assuntos
Assistência à Saúde/economia , Dengue/economia , Dengue/terapia , Hospitalização/economia , Hospitais Privados/economia , Hospitais Públicos/economia , Saúde Pública/economia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Assistência à Saúde/estatística & dados numéricos , Dengue/epidemiologia , Feminino , Gastos em Saúde/estatística & dados numéricos , Hospitalização/estatística & dados numéricos , Hospitais Privados/estatística & dados numéricos , Hospitais Públicos/estatística & dados numéricos , Humanos , Índia/epidemiologia , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Saúde Pública/estatística & dados numéricos , Índice de Gravidade de Doença , Adulto Jovem
12.
Trends Parasitol ; 35(9): 673-676, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-31279656

RESUMO

Post-acute consequences currently form a significant component of the dengue disability-adjusted life year (DALY) burden estimates. However, there is considerable uncertainty regarding the incidence, duration, and severity of these symptoms. Further research is needed to more accurately estimate the health and economic burden of these dengue manifestations.


Assuntos
Efeitos Psicossociais da Doença , Dengue/complicações , Incerteza , Dengue/economia , Humanos , Anos de Vida Ajustados por Qualidade de Vida
13.
PLoS One ; 14(7): e0219287, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31283788

RESUMO

BACKGROUND: Dengue is a public health problem, and noncompliance with World Health Organization (WHO) recommendations for blood transfusion components is frequently reported. Moreover, economic impact studies of the WHO recommendations on the use of blood transfusion are scarce. METHODS: We compared the cost and hospitalization time in a prospective observational study, by following hospitalised patients and analysing their medical records from 2010 and March 2016 to December 2017. We divided the patients into two groups: transfused (with or without WHO criteria for transfusion) and not transfused (with or without WHO criteria for transfusion). Generalised linear modelling was performed to identify the variable that could increase the costs and hospital stay. RESULTS: Among 323 patients, 52 were transfused, of whom 52% without criteria (n = 27), and 271 were not transfused, of which 4.4% (n = 12) with criteria. Hospitalisation costs were 41% higher in the transfused group without criteria than in those with criteria (median US$ 674.3 vs US$ 478 p = 0.293). Patients who were not transfused but met the WHO criteria for transfusion (n = 12) had longer mean hospitalisation time than did those who were not transfused (3.8±3.4 days versus 3.6±3.1 days; p = 0.022). The GLM analysis using hospital stay and costs as the dependent variable explained approximately 33.4% (R2 = 0.334) of the hospitalisation time and 79.3% (R2 = 0.793) of costs. Receiving a transfusion increased the hospitalization time by 1.29 days (p = 0.0007; IRR = 1.29), and the costs were 5.1 times higher than those without receiving blood components (IRR = 5.1; p< 0.001; median US$ 504.4 vs US$ 170.7). In contrast, patients who were transfused according to WHO criteria had a reduction in costs of approximately 96% (IRR = 0.044; p<0.001; ß = -3.12) compared to that for those who were not transfused according to WHO criteria (without criteria). CONCLUSION: Transfusion without following WHO recommendations increased the time and cost of hospitalisation.


Assuntos
Transfusão de Sangue/economia , Transfusão de Sangue/métodos , Dengue/economia , Adolescente , Adulto , Idoso , Brasil , Criança , Pré-Escolar , Dengue/sangue , Feminino , Custos Hospitalares , Hospitalização/economia , Humanos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Saúde Pública/economia
14.
Value Health Reg Issues ; 18: 132-144, 2019 May.
Artigo em Inglês | MEDLINE | ID: mdl-31082793

RESUMO

OBJECTIVES: To review the literature on the cost-effectiveness of dengue vaccination in Southeast Asian countries and possibly to provide recommendations on promoting dengue vaccination in this region. METHODS: A systematic search was conducted to identify relevant articles in 3 major databases (ProQuest, American Society of Tropical Medicine and Hygiene, and PubMed). Complete economic evaluation studies, including willingness-to-pay (WTP) studies, that were conducted in any Southeast Asian country were included in this study. Systematic review, non-full-text, and non-English studies were specifically excluded. RESULTS: Nine selected studies highlighted the economic evaluation of dengue vaccination in Southeast Asian countries by considering many parameters (eg, vaccine cost, vaccine efficacy, cost-effectiveness threshold, economic assessment, public acceptance, and WTP). All studies confirmed that dengue vaccine can be used as a prevention strategy to reduce the incidence rate of dengue cases by providing a variance of high cost-effectiveness values. In addition, communities provided a good assessment, acceptance, and WTP value for the vaccine. CONCLUSIONS: The use of dengue vaccine could reduce the burden of disease and economic burden due to dengue infection in Southeast Asian countries. The efficacy of dengue vaccine was estimated to be 50-95% for those <9 years, 9 years, and >9 years. In particular, several studies reported that dengue vaccine could be categorized as a cost-effective intervention in Southeast Asian countries within certain conditions.


Assuntos
Vacinas contra Dengue/economia , Dengue/prevenção & controle , Ásia Sudeste , Análise Custo-Benefício , Dengue/economia , Dengue/epidemiologia , Humanos
15.
Am J Trop Med Hyg ; 100(6): 1525-1533, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-30994088

RESUMO

Although the costs of dengue illness to patients and households have been extensively studied in endemic populations, international travelers have not been the focus of costing studies. As globalization and human travel activities intensify, travelers are increasingly at risk for emerging and reemerging infectious diseases, such as dengue. This exploratory study aims to investigate the impact and out-of-pocket costs of dengue illness among travelers. We conducted a prospective study in adult travelers with laboratory-confirmed dengue and recruited patients at travel medicine clinics in eight different countries from December 2013 to December 2015. Using a structured questionnaire, we collected information on patients and their health-care utilization and out-of-pocket expenditures, as well as income and other financial losses they incurred because of dengue illness. A total of 90 patients participated in the study, most of whom traveled for tourism (74%) and visited countries in Asia (82%). Although 22% reported hospitalization and 32% receiving ambulatory care while traveling, these percentages were higher at 39% and 71%, respectively, after returning home. The out-of-pocket direct and indirect costs of dengue illness were US$421 (SD 744) and US$571 (SD 1,913) per episode, respectively, averaging to a total out-of-pocket cost of US$992 (SD 2,052) per episode. The study findings suggest that international travelers incur important direct and indirect costs because of dengue-related illness. This study is the first to date to investigate the impact and out-of-pocket costs of travel-related dengue illness from the patient's perspective and paves the way for future economic burden studies in this population.


Assuntos
Dengue/economia , Dengue/terapia , Gastos em Saúde , Doença Relacionada a Viagens , Viagem , Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Aceitação pelo Paciente de Cuidados de Saúde , Estudos Prospectivos , Adulto Jovem
16.
Rev. cuba. med. trop ; 71(1): e323, ene.-abr. 2019. tab
Artigo em Espanhol | LILACS, CUMED | ID: biblio-1093544

RESUMO

Introducción: En Cuba hay pocos datos disponibles sobre la pérdida de calidad de vida relacionada con la salud y la carga económica para los pacientes de dengue y sus familiares. Objetivo: Describir la pérdida de calidad de vida relacionada con la salud y la carga económica del dengue para los pacientes y sus familiares. Métodos: Se aplicó un cuestionario a 92 pacientes adultos confirmados de dengue y hospitalizados en el Hospital Clínico Quirúrgico Docente Ambrosio Grillo de Santiago de Cuba, entre enero y octubre 2015; también se les aplicó a sus familias. Se calculó la pérdida promedio de calidad de vida a través de una escala analógica (0-100) y de los costos no médicos directos (gastos de bolsillo) e indirectos por paciente. Resultados: la pérdida global de calidad de vida fue de 67,9 por ciento en el peor momento de la enfermedad. El promedio de días autopercibidos hasta la recuperación fue 13,1. El promedio de visitas por paciente a los servicios ambulatorios antes de la hospitalización fue 1,3, y el policlínico resultó el servicio más utilizado. La estadía hospitalaria promedio fue 3,96 noches. Ningún enfermo presentó dengue grave. Los costos no médicos directos para los pacientes y sus familiares, fueron 7,95 USD (CUC). El 44,7 por ciento fue utilizado en transporte y 32,0 por ciento en alimentación, financiados principalmente con los ahorros personales y donaciones de familiares y amigos. Los costos indirectos promedio fueron 4,10 USD (CUC). Conclusión: Hubo una sustancial pérdida de calidad de vida durante la enfermedad. Los costos no médicos directos y los indirectos para los pacientes y familiares fueron bajos. La carga económica asumida por el gobierno es 12 veces mayor que estos(AU)


Introduction: Few data are available in Cuba about the loss of health-related quality of life and the economic burden caused by dengue fever to patients and their families. Objective: Describe the loss of health-related quality of life and the economic burden caused by dengue fever to patients and their families in Santiago de Cuba. Method: A questionnaire was applied to 92 adult patients with confirmed dengue fever admitted to Ambrosio Grillo Clinical Surgical University Hospital in Santiago de Cuba from January to October 2015. The questionnaire was also applied to their relatives. An analog scale (0-100) was used to estimate average loss of quality of life as well as indirect and direct non-medical costs expenses incurred by patients. Results: Global loss of quality of life was 67.9 percent at the worst stage of the condition. Average self-perceived days until recovery were 13.1. Average visits to outpatient services per patient before hospitalization were 1.3. The polyclinic was the most commonly used service. Average hospital stay was 3.96 nights. No patient had severe dengue fever. Direct non-medical expenses incurred by patients and their families were USD 7.95 (CUC), 44.7 percent of which were spent on transportation and 32.0 percent on food. These were mainly covered by personal savings and donations from relatives and friends. Average indirect expenses were USD 4.10 (CUC). Conclusion: There was considerable loss of quality of life during the disease. Patients and their families incurred low non-medical direct and indirect expenses. The economic burden undertaken by the government is 12 times as high(AU)


Assuntos
Humanos , Masculino , Feminino , Qualidade de Vida , Dengue/economia , Dengue/psicologia , Cuba/epidemiologia
17.
PLoS Negl Trop Dis ; 13(2): e0007164, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-30817776

RESUMO

BACKGROUND: Dengue fever is a rapidly growing public health problem in many parts of the tropics and sub-tropics in the world. While there are existing studies on the economic burden of dengue fever in some of dengue-endemic countries, cost components are often not standardized, making cross-country comparisons challenging. Furthermore, no such studies have been available in Africa. METHODS/PRINCIPAL FINDINGS: A patient-specific survey questionnaire was developed and applied in Burkina Faso, Kenya, and Cambodia in a standardized format. Multiple interviews were carried out in order to capture the entire cost incurred during the period of dengue illness. Both private (patient's out-of-pocket) and public (non-private) expenditure were accessed to understand how the economic burden of dengue is distributed between private and non-private payers. A substantial number of dengue-confirmed patients were identified in all three countries: 414 in Burkina Faso, 149 in Kenya, and 254 in Cambodia. The average cost of illness for dengue fever was $26 (95% CI $23-$29) and $134 (95% CI $119-$152) per inpatient in Burkina Faso and Cambodia, respectively. In the case of outpatients, the average economic burden per episode was $13 (95% CI $23-$29) in Burkina Faso and $23 (95% CI $19-$28) in Kenya. Compared to Cambodia, public contributions were trivial in Burkina Faso and Kenya, reflecting that a majority of medical costs had to be directly borne by patients in the two countries. CONCLUSIONS/SIGNIFICANCE: The cost of illness for dengue fever is significant in the three countries. In particular, the current study sheds light on the potential economic burden of the disease in Burkina Faso and Kenya where existing evidence is sparse in the context of dengue fever, and underscores the need to achieve Universal Health Coverage. Given the availability of the current (CYD-TDV) and second-generation dengue vaccines in the near future, our study outcomes can be used to guide decision makers in setting health policy priorities.


Assuntos
Efeitos Psicossociais da Doença , Dengue/economia , Dengue/epidemiologia , Saúde Pública/economia , Burkina Faso/epidemiologia , Camboja/epidemiologia , Custos de Cuidados de Saúde , Humanos , Quênia/epidemiologia
18.
PLoS One ; 14(3): e0211034, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30893309

RESUMO

Increasing incidences of dengue have become a global health threat with major clinical manifestation including high fever and gastrointestinal symptoms. These symptoms were also expressed among Blastocystis sp. infected individuals, a parasite commonly seen in human stools. This parasite has been previously reported to replicate faster upon exposure to high temperature. The present study is a hospitalized-based cross-sectional study involved the collection of faecal sample from dengue patients. Stool examination was done by in vitro cultivation to isolate Blastocystis sp. Growth pattern of all the positive isolates were analyzed to identify the multiplication rate of Blastocystis sp. isolated from dengue patients. Distribution of Blastocystis sp. among dengue patients was 23.6%. Dengue patients who were positive for Blastocystis sp. infection denoted a significantly higher fever rate reaching 38.73°C (p<0.05) compared to the non-Blastocystis sp. infected patients (38.44°C). It was also found that Blastocystis sp. infected patients complained of frequenting the toilet more than five times a day (p<0.05) compared to those who were non-Blastocystis sp. infected. At the same time, the duration of hospitalization was significantly longer (p<0.05) for Blastocystis sp. infected dengue patients compared to the non-Blastocystis sp. infected patients. Besides, Blastocystis sp. isolated from dengue patients (in vivo thermal stress) showed a higher growth rate compared to the non-dengue isolated which was exposed to high temperature (in vitro thermal stress). Our findings suggest that presence of Blastocystis sp. during dengue infection could trigger the increase of temperature which could be due to highly elevated pro inflammatory cytokines by both parasitic and virus infection. This could justify why the temperature in Blastocystis sp. infected dengue patients is higher compared to the non-Blastocystis sp. infected patients. Higher temperature could have triggered a greater parasite multiplication rate that contributed to the aggravation of the gastrointestinal symptoms.


Assuntos
Infecções por Blastocystis/metabolismo , Dengue/complicações , Dengue/economia , Adulto , Blastocystis/isolamento & purificação , Blastocystis/metabolismo , Infecções por Blastocystis/parasitologia , Estudos Transversais , Dengue/microbiologia , Fezes/parasitologia , Feminino , Febre , Gastroenteropatias , Custos de Cuidados de Saúde , Humanos , Malásia , Masculino
19.
Int J Infect Dis ; 84S: S64-S67, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-30826484

RESUMO

OBJECTIVES: To describe the direct cost of illness in pediatric and adult inpatients at a referral hospital in India. METHODS: Inpatients who tested positive for dengue were identified in the hospital records of a single private non-profit hospital over a period of 1 year and line-listed. Hospital discharge bills were obtained for pediatric and adult patients and the median costs by severity of illness for bed and treatment were estimated. Costs were also converted to US dollars (1 USD=64.6 Indian rupees (INR)). RESULTS: The median and interquartile range (IQR) direct costs for pediatric dengue without warning signs, dengue with warning signs, and severe dengue were 179.80 (IQR 85.51-428.51) USD, 145.06 (IQR 90.89-321.86) USD, and 933.51 (IQR 400.50-1117.43) USD, respectively. The median and IQR direct costs for adult dengue without warning signs, dengue with warning signs, and severe dengue were 312.75 (IQR 174.55-531.03) USD, 287.22 (IQR 210.96-389.34) USD, and 720.39 (IQR 389.23-1035.51) USD, respectively. CONCLUSIONS: Children and adults with dengue incur high costs when hospitalized for dengue. Since most medical costs in India are out-of-pocket expenses, these illnesses can impact households.


Assuntos
Efeitos Psicossociais da Doença , Dengue/economia , Dengue/terapia , Encaminhamento e Consulta/economia , Adolescente , Criança , Criança Hospitalizada/estatística & dados numéricos , Pré-Escolar , Feminino , Gastos em Saúde , Humanos , Masculino , Alta do Paciente
20.
PLoS One ; 14(2): e0211401, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30785894

RESUMO

BACKGROUND: Studies on dengue related to the cost of illness and cost of the program are factors to describe the economic burden of dengue, a neglected disease that has global importance in public health. These studies are often used by health managers in optimizing financial resources. A systematic review of studies estimating the cost of dengue was carried out, comparing the costs between the studies and examining the cost drivers regarding the methodological choices. METHODS: This study was done according to the guidelines of the Centre for Reviews and Dissemination (CRD). Several databases were searched: Medline, Virtual Health Library and CRD. Two researchers, working independently, selected the studies and extracted the data. The quality of the methodology of the individual studies was achieved by a checklist of 29 items based on protocols proposed by the British Medical Journal and Consolidated Health Economic Evaluation Reporting Standards. A qualitative and quantitative narrative synthesis was performed. RESULTS: A literature search yielded 665 publications. Of these, 22 studies are in accordance with previously established inclusion criteria. The cost estimates were compared amongst the studies, highlighting the study design, included population and comparators used (study methodology). The component costs included in the economic evaluation were based on direct and indirect costs, wherein twelve studies included both costs, twelve studies adopted the societal perspective and ten studies used the perspective of the public health service provider, or of a private budget holder. CONCLUSION: This study showed that the cost of dengue in 18 countries generated approximately US$ 3.3 billion Purchasing Power Parity (PPP) in 2015. This confirms that the burden of dengue has a great economic impact on countries with common socioeconomic characteristics and similarities in health systems, particularly developing countries, indicating a need for further studies in these countries.


Assuntos
Dengue/economia , Efeitos Psicossociais da Doença , Humanos , Saúde Pública/economia , Prática de Saúde Pública/economia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA